CR10940A - Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos - Google Patents

Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos

Info

Publication number
CR10940A
CR10940A CR10940A CR10940A CR10940A CR 10940 A CR10940 A CR 10940A CR 10940 A CR10940 A CR 10940A CR 10940 A CR10940 A CR 10940A CR 10940 A CR10940 A CR 10940A
Authority
CR
Costa Rica
Prior art keywords
therapy
neoadjutive
adjutive
stays
early
Prior art date
Application number
CR10940A
Other languages
English (en)
Inventor
Napoleone Ferrara
Nina Korsisaari
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR10940A publication Critical patent/CR10940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se divulgan metodos de tratamiento de tumores benignos, precancerosos o no metastasicos usando un antagonista especifico anti-VEGF. Tambien se describen metodos de tratamiento de un sujeto en riesgo de desarrollar un tumor benigno, precanceroso o no metastasico usando un antagonista especifico anti-VEGF, asi como el uso de antagonistas especificos de VEGF en terapia de cancer adyuvante y neoadyuvante.
CR10940A 2006-12-19 2009-07-17 Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos CR10940A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87074506P 2006-12-19 2006-12-19
US87074106P 2006-12-19 2006-12-19
US87726706P 2006-12-27 2006-12-27
US91963807P 2007-03-22 2007-03-22
US95838407P 2007-07-05 2007-07-05
US98939707P 2007-11-20 2007-11-20

Publications (1)

Publication Number Publication Date
CR10940A true CR10940A (es) 2009-08-13

Family

ID=39323719

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10940A CR10940A (es) 2006-12-19 2009-07-17 Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos

Country Status (27)

Country Link
US (6) US20080248033A1 (es)
EP (2) EP3095455A1 (es)
JP (4) JP2010513566A (es)
KR (5) KR20140148491A (es)
CN (1) CN103143017A (es)
AR (1) AR064458A1 (es)
AU (1) AU2007333735A1 (es)
BR (1) BRPI0720552A2 (es)
CA (1) CA2671734A1 (es)
CO (1) CO6210829A2 (es)
CR (1) CR10940A (es)
DK (1) DK2101807T3 (es)
EC (1) ECSP099523A (es)
ES (1) ES2582656T3 (es)
HU (1) HUE029445T2 (es)
IL (1) IL238913A0 (es)
MA (1) MA31150B1 (es)
MX (1) MX2009006779A (es)
MY (1) MY183404A (es)
NO (1) NO20092604L (es)
NZ (1) NZ578472A (es)
PL (1) PL2101807T3 (es)
RU (1) RU2013129450A (es)
SG (2) SG10201503407WA (es)
SI (1) SI2101807T1 (es)
TW (2) TWI577695B (es)
WO (1) WO2008077077A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
DK2361085T4 (en) * 2008-11-22 2018-10-08 Hoffmann La Roche USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
JP2012517434A (ja) * 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
AR076344A1 (es) * 2009-04-20 2011-06-01 Genentech Inc Metodo de terapia complementaria contra el cancer
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
US9387211B2 (en) 2010-02-01 2016-07-12 Cedars-Sinai Medical Center Methods for treatment of Cushing'S disease and hypercortisolism using gefitinib
US20120308567A1 (en) * 2010-02-01 2012-12-06 Cedars-Sinai Medical Center Use of tyrosine kinase inhibitors for treatment of prolactinoma
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
SG187012A1 (en) * 2010-07-19 2013-02-28 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2012135624A1 (en) * 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
WO2012151574A1 (en) 2011-05-05 2012-11-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN103957923B (zh) * 2011-09-12 2018-05-25 卡维昂公司 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US20130142796A1 (en) * 2011-12-05 2013-06-06 Subhransu Ray Treatment for angiogenic disorders
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
JP6445451B2 (ja) 2012-12-03 2018-12-26 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
AU2016381656A1 (en) * 2015-12-30 2018-07-12 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of chemoprevention
WO2017201166A1 (en) * 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
EP3727468A4 (en) * 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US11026649B2 (en) * 2018-06-25 2021-06-08 Siemens Medical Solutions Usa, Inc. Method and system for determining tumor burden in medical images
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
SG11202107334RA (en) * 2019-02-18 2021-08-30 Agency Science Tech & Res A membrane-bound fit-1 decoy and uses thereof
CN114096240A (zh) * 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN112773852A (zh) * 2021-03-16 2021-05-11 宁夏医科大学 一种对细胞有保护作用的中草药组合物的制备工艺
CN113512589B (zh) * 2021-07-14 2023-03-10 复旦大学附属中山医院 Prune1基因检测在多发性骨髓瘤患者预后中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP2001072587A (ja) * 1999-07-01 2001-03-21 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050044853A1 (en) * 2003-09-02 2005-03-03 Kazutora Yoshino Ecology system
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
SI1771474T1 (sl) * 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba

Also Published As

Publication number Publication date
PL2101807T3 (pl) 2016-11-30
JP2010513566A (ja) 2010-04-30
KR20140148491A (ko) 2014-12-31
ES2582656T3 (es) 2016-09-14
WO2008077077A3 (en) 2008-08-14
SG10201503407WA (en) 2015-06-29
CN103143017A (zh) 2013-06-12
US20180208647A1 (en) 2018-07-26
DK2101807T3 (en) 2016-08-29
US20160108116A1 (en) 2016-04-21
EP2101807A2 (en) 2009-09-23
KR20130060309A (ko) 2013-06-07
KR20150097813A (ko) 2015-08-26
WO2008077077A2 (en) 2008-06-26
SI2101807T1 (sl) 2016-08-31
AR064458A1 (es) 2009-04-01
HUE029445T2 (en) 2017-02-28
CO6210829A2 (es) 2010-10-20
EP2101807B1 (en) 2016-05-25
US20110052576A1 (en) 2011-03-03
US20080248033A1 (en) 2008-10-09
BRPI0720552A2 (pt) 2014-01-07
MX2009006779A (es) 2009-08-27
TWI577695B (zh) 2017-04-11
JP2018052939A (ja) 2018-04-05
KR20090097188A (ko) 2009-09-15
US20120148584A1 (en) 2012-06-14
KR20140031996A (ko) 2014-03-13
MY183404A (en) 2021-02-18
US20140178363A1 (en) 2014-06-26
IL238913A0 (en) 2015-06-30
RU2013129450A (ru) 2015-01-10
EP3095455A1 (en) 2016-11-23
ECSP099523A (es) 2009-09-29
CA2671734A1 (en) 2008-06-26
AU2007333735A2 (en) 2009-11-05
TW201525003A (zh) 2015-07-01
SG176448A1 (en) 2011-12-29
JP2013189452A (ja) 2013-09-26
NO20092604L (no) 2009-09-18
JP2015110609A (ja) 2015-06-18
HK1133210A1 (zh) 2010-03-19
AU2007333735A1 (en) 2008-06-26
NZ578472A (en) 2012-06-29
MA31150B1 (fr) 2010-02-01
TW200831538A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
CR10940A (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
CY1116847T1 (el) Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
NO20084546L (no) Diagnostikk og behandlinger for tumorer
IL258880A (en) Diarylhydantoin compounds
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
NO20082683L (no) Neuroendokrin tumorbehandling
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CR9477A (es) Numero de copias del gen del receptor del factor de crecimiento epidermico
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
CL2007002951A1 (es) Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer.
EA200801430A1 (ru) Производные триазола
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof
CY1116492T1 (el) Δραστηριοτητα του τεμσιρολιμου κατα των ογκων στον καρκινο θηλοειδων νεφρικων κυτταρων
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.